TOP PHARM CO.,LIMITED

About Us
Factory Tour
Quality Control
Contact Us
Home ProductsOral Anabolic Steroids

99% Purity Cabergoline CAS 81409-90-7 White powder Treatment 0f high prolactin levels,prolactinoma

99% Purity Cabergoline CAS 81409-90-7 White powder Treatment 0f high prolactin levels,prolactinoma

  • 99% Purity Cabergoline CAS 81409-90-7 White powder Treatment  0f  high prolactin levels,prolactinoma
  • 99% Purity Cabergoline CAS 81409-90-7 White powder Treatment  0f  high prolactin levels,prolactinoma
  • 99% Purity Cabergoline CAS 81409-90-7 White powder Treatment  0f  high prolactin levels,prolactinoma
  • 99% Purity Cabergoline CAS 81409-90-7 White powder Treatment  0f  high prolactin levels,prolactinoma
99% Purity Cabergoline CAS 81409-90-7 White powder Treatment  0f  high prolactin levels,prolactinoma
Product Details:
Place of Origin: China
Brand Name: Top Pharm
Certification: IOS 901
Model Number: 81409-90-7
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Price: Negotiable
Packaging Details: As your requirments
Delivery Time: 3-6 working days
Payment Terms: T/T, Western Union, MoneyGram,bitcoin
Supply Ability: bulk stock
Contact Now
Detailed Product Description
Purity: 99% Appearance: White Loose Lyophilized Powder.
Spec: 10G CAS: 81409-90-7
MF: C26H37N5O2 MW: 451.6
High Light:

organic oral steroids

,

bodybuilding oral anabolic steroids

Cabergoline


Alias: Cabaser, Dostinex; Dostine, 6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
CAS: 81409-90-7
Molecular Formula: C26H37N5O2
Molecular Weight: 451.6
Melting Point: 102-104° C


 

 

Cabergoline

 

From Wikipedia, the free encyclopedia
 
 
 
Jump to navigationJump to search
Cabergoline
 
Clinical data
Trade names Dostinex, others
AHFS/Drugs.com Monograph
License data
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability First-pass effect seen; absolute bioavailability unknown
Protein binding Moderately bound (40–42%); concentration-independent
Metabolism Hepatic, predominately via hydrolysis of the acylurea bond or the urea moiety
Elimination half-life 63–69 hours (estimated)
Excretion Urine (22%), feces (60%)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.155.380 Edit this at Wikidata
Chemical and physical data
Formula C26H37N5O2
Molar mass 451.615 g·mol−1
3D model (JSmol)
☒check (what is this?) (verify)

Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth.

Cabergoline is an ergot derivative and a potent dopamine D2 receptor agonist.

Cabergoline was patented in 1980 and approved for medical use in 1993.

Medical uses[edit]

Cabergoline is frequently used as a first-line agent in the management of prolactinomas due to its higher affinity for D2 receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine, though in pregnancy bromocriptine is often still chosen since there is less data on safety in pregnancy for cabergoline.

Off-label[edit]

It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs, such as reduced libido and anorgasmia. It also has been suggested that it has a possible recreational use in reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession, and at least two scientific studies support those speculations. Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF). Also, a study on rats found that cabergoline reduces voluntary alcohol consumption, possibly by increasing GDNF expression in the ventral tegmental area.It may be used in the treatment of restless legs syndrome.[citation needed]

Pregnancy and lactation

 

Side effects are mostly dose dependent. Much more severe side effects are reported for treatment of Parkinson's disease and (off-label treatment) for restless leg syndrome which both typically require very high doses. The side effects are considered mild when used for treatment of hyperprolactinemia and other endocrine disorders or gynecologic indications where the typical dose is one hundredth to one tenth that for Parkinson's disease.[citation needed]

Cabergoline requires slow dose titration (2–4 weeks for hyperprolactinemia, often much longer for other conditions) to minimise side effects. The extremely long bioavailability of the medication may complicate dosing regimens during titration and require particular precautions.

Cabergoline is considered the best tolerable option for hyperprolactinemia treatment although the newer and less tested quinagolide may offer similarly favourable side effect profile with quicker titration times.

Approximately 200 patients with newly diagnosed Parkinson's disease participated in a clinical study of cabergoline monotherapy. Seventy-six (76) percent reported at least one side effect. These side effects were chiefly mild or moderate:

In a combination study with 2,000 patients also treated with levodopa, the incidence and severity of side effects was comparable to monotherapy. Encountered side effects required a termination of cabergoline treatment in 15% of patients. Additional side effects were infrequent cases of hematological side effects, and an occasional increase in liver enzymes or serum creatinine without signs or symptoms.

As with other ergot derivatives, pleuritis, exudative pleura disease, pleura fibrosis, lung fibrosis, and pericarditis are seen. These side effects are noted in less than 2% of patients. They require immediate termination of treatment. Clinical improvement and normalization of X-ray findings are normally seen soon after cabergoline withdrawal. It appears that the dose typically used for treatment of hyperprolactinemia is too low to cause this type of side effects.

Valvular heart disease

In two studies published in the New England Journal of Medicine on January 4, 2007, cabergoline was implicated along with pergolide in causing valvular heart disease. As a result of this, the FDA removed pergolide from the U.S. market on March 29, 2007.[14] Since cabergoline is not approved in the U.S. for Parkinson's Disease, but for hyperprolactinemia, the drug remains on the market. The lower doses required for treatment of hyperprolactinemia have been found to be not associated with clinically significant valvular heart disease or cardiac valve regurgitation.[

 

 

Polypeptide Hormones we supply
Melanotan II CAS 121062-08-6 timulate the body's tanning response
Selank CAS 129954-34-3 help enhance mental sharpness,enhance memory
DSIP CAS 62568-57-4 Delta sleep-inducing peptide, abbreviated DSIP
Gonadotropin CAS 71447-49-9 Mainly used for prostate cancer
Tesamorelin CAS 218949-48-5 used in the treatment of HIV-associated lipodystrophy
Triptorelin CAS 57773-63-4 used as the acetate or pamoate salts
HG 176-191   the fat-reducing effects
Pentadecapeptide BPC 157 CAS 137525-51-0 increasing lean muscular tissue mass, reducing fat
TB500 CAS 77591-33-4 oincrease muscle growth
Oxytocin CAS 50-56-6 used for stimulation of uterus contractions
Sermorelin CAS 86168-78-7 Increases the development of lean body mass
Hexarelin CAS 140703-51-1 the treatment of growth hormone secretion deficiency
Ipamorelin CAS 170851-70-4 a selective growth hormone secretagogue
Melanotan 1 CAS 75921-69-6 endogenous melanocortine peptide
MGF   used by bodybuilders and athletes
PEG-MGF   cause site specific muscle growth
CJC-1295 Without DAC CAS 863288-34-0 increasing binding affinity to the GHRH receptors
CJC-1295 with DAC CAS 863288-34-0 improved physique and sense of well being
PT-141   increase libido effects of both men and women
GHRP-2 CAS 158861-67-7 growth hormone stimulation
GHRP-6 CAS 87616-84-0 Increase in strength,Muscle mass,Body fat loss
Tb-500 CAS 77591-33-4 increases in endurance,strength and muscle growth

 

 

 

 

 

 

99% Purity Cabergoline CAS 81409-90-7 White powder Treatment  0f  high prolactin levels,prolactinoma 10

Contact Details
TOP PHARM CO.,LIMITED

Contact Person: Baron

Tel: +8618627186113

Send your inquiry directly to us (0 / 3000)